Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned for... read full story
Ask about this article
Related News
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Form 6 K (Immuron Limited)
Public Technologies 2024-09-26, 12:54Related News
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
Pharmiweb2024-11-18, 14:28
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease - Form 6-K (Immuron Limited)
Public Technologies2022-07-07, 13:00
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
The Associated Press2023-01-17, 12:19
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile ...
Eagle-Tribune2023-01-17, 13:32
FY22 Results and Business Update Presentation (Immuron Limited)
Public Technologies2022-08-31, 02:04